Kkprazole-PDSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to provide effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing gastric emptying and reducing symptoms of nausea and vomiting. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, thereby providing symptomatic relief from acid-related disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The synergistic action of these two agents offers comprehensive treatment by addressing both delayed gastric emptying and excessive acid production. Kkprazole-PDSR is indicated for patients experiencing upper gastrointestinal symptoms including heartburn, acid regurgitation, epigastric pain, and dyspepsia, especially where delayed gastric emptying is a contributing factor. The medication should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with cardiac arrhythmias or electrolyte imbalances. Adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage ensure optimal therapeutic outcomes with Kkprazole-PDSR Capsule.